Extended dosing (12 cycles) vs conventional dosing (6 cycles) of adjuvant temozolomide in adults with newly diagnosed high-grade gliomas: a randomized, single-blind, two-arm, parallel-group controlled trial.
Saved in:
| Title: | Extended dosing (12 cycles) vs conventional dosing (6 cycles) of adjuvant temozolomide in adults with newly diagnosed high-grade gliomas: a randomized, single-blind, two-arm, parallel-group controlled trial. |
|---|---|
| Authors: | Anvari K; Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran., Seilanian Toussi M; Department of Urology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States., Saghafi M; Qazvin University of Medical Sciences, Qazvin, Qazvin, Iran., Javadinia SA; Non-Communicable Diseases Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran., Saghafi H; Faculty of Medicine, Tehran Medical Branch of Islamic Azad University, Tehran, Iran., Welsh JS; Department of Radiation Oncology, Loyola University Chicago Stritch School of Medicine, Edward Hines Jr., VA Hospital, Maywood, IL, United States. |
| Source: | Frontiers in oncology [Front Oncol] 2024 May 07; Vol. 14, pp. 1357789. Date of Electronic Publication: 2024 May 07 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2024.1357789 |
